Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
- Conditions
- Malignant Neoplasm
- Interventions
- Drug: Megestrol acetate/Medroxyprogesterone acetateDrug: Fludrocortisone/ Fludrocortisone acetateDrug: Dexamethasone/Dexamethasone acetateDrug: Rescue Medications
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 250
- Registration Number
- NCT06979596
A Clinical Study of HRS-6209 in Combination With Letrozole in Patients With Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: HRS-6209 Capsules
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06974929
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
- Conditions
- HR+/HER2- Advanced/Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT06957379
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
- Conditions
- HER2 Negative Breast Cancer
- Interventions
- Drug: Anastrazole 1mgRadiation: Adjuvant chemotherapy
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Yale University
- Target Recruit Count
- 140
- Registration Number
- NCT06953882
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2883
- Registration Number
- NCT06930859
Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 240
- Registration Number
- NCT06905301
Laboratory and Ultrasound Findings and Response to Letrozole in PCOS Patients
- Conditions
- PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
- Interventions
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Al-Azhar University
- Target Recruit Count
- 138
- Registration Number
- NCT06861803
- Locations
- 🇪🇬
Al-Hussein University Hospital, Cairo, Egypt
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 450
- Registration Number
- NCT06790693
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1020
- Registration Number
- NCT06760637
- Locations
- 🇧🇬
Complex Oncology Center - Shumen, Shumen, Bulgaria
🇺🇸Ironwood Cancer & Research Centers, Scottsdale, Arizona, United States
🇺🇸Highlands Oncology, Rogers, Arkansas, United States
Letrozole Versus Mifepristone and Misoprostol in Silent Miscarriage
- Conditions
- Silent Miscarriage
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 884
- Registration Number
- NCT06733727
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.